To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Validation of a new assay… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Validation of a new assay for α-synuclein detection in cerebrospinal fluid.

Journal article
Authors Marthe Gurine Førland
Annika Öhrfelt
Linn Silje Oftedal
Ole-Bjørn Tysnes
Jan Petter Larsen
Kaj Blennow
Henrik Zetterberg
Guido Alves
Johannes Lange
Published in Clinical chemistry and laboratory medicine
Volume 55
Issue 2
Pages 254–260
ISSN 1437-4331
Publication year 2017
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 254–260
Language en
Links dx.doi.org/10.1515/cclm-2016-0409
Subject categories Neurochemistry

Abstract

Abnormal α-synuclein aggregation and deposition is the pathological hallmark of Parkinson's disease (PD) and dementia with Lewy bodies (DLB), but is also found in Alzheimer disease (AD). Therefore, there is a gaining interest in α-synuclein in cerebrospinal fluid (CSF) as potential biomarker for these neurodegenerative diseases. To broaden the available choices of α-synuclein measurement in CSF, we developed and validated a new assay for detecting total α-synuclein.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?